Table 3

Mutational analyses of resistant disease or relapse/progression specimens

OutcomePatients, N = 25Patients with mutation data, N = 22Specimen collection times
Imatinib 400 mg/d    
    Stable disease 1Mut: M244V 31 days before removal from protocol treatment 
3 WT 22 days before and 103 days after removal from protocol treatment; day 371 of protocol treatment 
    Relapse from CHR 1 Mut: E453K 63 days before relapse 
7 WT 6, 7, 14, 24, 78, and 672 days before; 658 days after relapse 
    Progression 1 WT 4 days before removal from protocol treatment due to progression (patient was not adequately assessed for response) 
Dasatinib 100 mg/d    
    Stable disease 4 WT 111 days before removal from protocol treatment; days 96, 329 and 374 of protocol treatment 
    Relapse from CHR 1Mut: V299L Day of relapse 
3 WT 52, 264, and 364 days before relapse 
    Cytogenetic relapse 1 WT Day of cytogenetic relapse 
OutcomePatients, N = 25Patients with mutation data, N = 22Specimen collection times
Imatinib 400 mg/d    
    Stable disease 1Mut: M244V 31 days before removal from protocol treatment 
3 WT 22 days before and 103 days after removal from protocol treatment; day 371 of protocol treatment 
    Relapse from CHR 1 Mut: E453K 63 days before relapse 
7 WT 6, 7, 14, 24, 78, and 672 days before; 658 days after relapse 
    Progression 1 WT 4 days before removal from protocol treatment due to progression (patient was not adequately assessed for response) 
Dasatinib 100 mg/d    
    Stable disease 4 WT 111 days before removal from protocol treatment; days 96, 329 and 374 of protocol treatment 
    Relapse from CHR 1Mut: V299L Day of relapse 
3 WT 52, 264, and 364 days before relapse 
    Cytogenetic relapse 1 WT Day of cytogenetic relapse 

CHR indicates complete hematologic response; Mut, mutation; and WT, wild type.

or Create an Account

Close Modal
Close Modal